Loading quotes...
Forecast
The analysts' average price target is €275.55 (-13.03%). The median is €291.32 (-8.06%).
| Buy |
27 |
| Hold |
10 |
| Sell |
0 |
News Go to news feed
Charles River sparks rally: AI demand, raised annual targets and cost-cutting program support shares
AI-driven drug discovery boosts demand for laboratory testing, from which Charles River, as a top beneficiary, is profiting. After quarterly results from Danaher and Medpace, investors have been buying more aggressively, putting Charles River at the forefront of the rally. The company reports full order books, has raised its annual targets and launched a cost-saving program; third-quarter results will be the next acid test. » More on finanzen.net
Charles River Laboratories bets on digitization with Apollo Orchestrate and sets new long-term targets
Charles River Laboratories aims for annual organic revenue growth of 5–7% for 2027–2030 and an operating margin of around 24%. The new technology Apollo Orchestrate digitizes lab processes from sample submission to release and reduces administrative workload. Automation and paperless quality controls are intended to minimize audit risks and, as structural efficiency drivers, strengthen profitability. » More on finanzen.net
Charles River raises 2026 outlook and beats Q2 expectations
Charles River has significantly raised its full-year 2026 guidance and now expects adjusted earnings per share of $11.15 to $11.45 and revenue of up to $3.920 billion, both above the market consensus. In the second quarter the company beat expectations with adjusted EPS of $3.02 and revenue of $1.004 billion. Analysts reacted positively: TD Cowen confirmed its buy rating and raised the price target to $325. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 881.28m | 0.06% |
| Gross profit | 318.93m | 4.68% |
| Net profit | -1.3m | 102.91% |
| EBITDA | 132.36m | 29.78% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €14.87bn |
Number of shares | 48.17m |
52-week high/low | €313.84 - €130.65 |
| Dividends | No |
Beta | 1.40 |
P/E ratio | -71.36 |
PEG ratio | 0.74 |
P/B ratio | 5.90 |
P/S ratio | 4.16 |
Company profile
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
| Name | Charles River Labs Intl |
| CEO | Birgit Girshick |
| Headquarters | Wilmington,
ma USA |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 23/06/2000 |
| Employees | 19,000 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | CRL |
Frankfurt | RV6.F |
Düsseldorf | RV6.DU |
SIX | RV6.SW |
München | RV6.MU |